RT Journal Article
SR Electronic
A1 Helwick, Caroline
T1 Torcetrapib Fails to Meet Expectations
JF MD Conference Express
YR 2007
FD SAGE Publications
VO 7
IS 1
SP 17
OP 20
DO 10.1177/155989770700700109
UL http://mdc.sagepub.com/content/7/1/17.abstract
AB Increased levels of high-density lipoprotein cholesterol decrease the risk of cardiovascular disease. Torcetrapib, a cholesteryl-ester-transfer protein inhibitor, has a potent effect on increasing HDL-C levels that was hoped would translate into the halting or reversal of atherosclerosis. The results from three clinical trials of torcetrapib are discussed in this article.